TY  - JOUR
T1  - MOnoclonal antibody therapy in the treatment of non-hodgkin lymphoma
AU  - McCune SL, Gockerman JP, Rizzieri DA
Y1  - 2001/09/12
N1  - 10.1001/jama.286.10.1149
JO  - JAMA
SP  - 1149
EP  - 1152
VL  - 286
IS  - 10
N2  - 
Monoclonal antibodies are revolutionizing the treatment of many illnesses.
Some patients with coronary artery disease, Crohn disease, solid organ transplants,
rheumatoid arthritis, or cancer have already experienced benefits from these
engineered proteins. Monoclonal antibodies typically either harness the patient's
own immune system to fight disease or suppress an errant immune system. Table 1 lists the monoclonal antibodies
currently approved by the Food and Drug Administration (FDA); more than 50
others are in active clinical trials around the world. Monoclonal antibodies
are currently used by cardiologists, gastroenterologists, nephrologists, and
rheumatologists as well as oncologists. In this article, we focus on the use
of monoclonal antibodies for the treatment of patients with non-Hodgkin lymphoma
(NHL).

SN  - 0098-7484
M3  - doi: 10.1001/jama.286.10.1149
UR  - http://dx.doi.org/10.1001/jama.286.10.1149
ER  -